Vision, Skin Concerns Led Lyrica Reviewers To Consult Top FDA Staff, EMEA
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Top CDER officials moderated the primary reviewers' instincts to delay approval of Pfizer's Lyrica until more data on dermatologic and visual effects better characterized the drug's risks, review documents show